New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 27, 2012
07:26 EDTTBIO, WYY, VTSS, EGHT, CAMP, UPI, VRNG, ACLS, SPSC, CYBECraig-Hallum to host a conference
3rd Annual Alpha Select Conference is being held in New York on September 27.
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
09:19 EDTVRNGVringo updates on ZTE litigation in Brazil, Romania
Vringo provided an update on enforcement actions in Brazil and Romania against ZTE, as well as an update in its SDNY litigation and corporate matters. In Brazil, on June 24, the reporting appellate judge denied ZTE's latest request to overturn the injunction, rejecting a new interlocutory appeal, which requested an ex parte preliminary injunction in order to, upon payment of a bond, lift the original injunction. In addition, the trial court which issued the original injunction against ZTE ordered both parties to file briefs regarding the report by a court-appointed expert on the raid conducted at ZTE's Headquarters in São Paulo, which confirmed that ZTE violated the injunction. Vringo filed a brief on June 24, requesting further enforcement measures to secure ZTE's compliance with the injunction, and asking the court to order ZTE to pay an accumulated daily fine of approximately $2.5M for ZTE's violation of the injunction. Vringo expects a decision by the 5th Business Trial Court of Rio de Janeiro shortly. On June 19, ZTE Romania's latest attempt, a motion to cancel the January 8 decision which confirmed the preliminary injunction granted to Vringo against ZTE Romania and others, alleging that the Court made a material error when issuing that decision, was denied by the Bucharest Court of Appeal. In addition, based on documents recently obtained by Vringo, Vringo is currently investigating whether ZTE Romania and its retailers have breached the preliminary injunction. Vringo is currently assessing the legal remedies available to cure any violation. On June 23, the United States District Court for the Southern District of New York granted Vringo's motions to de-designate ZTE's responses to discovery requests, including those that reference ZTE's communications with the National Resources Development Counsel of the People's Republic of China, as "Highly Confidential - Attorneys Eyes Only - US Only". The Court's ruling will allow Vringo to participate more effectively in its breach of contract case against ZTE, in which the Court has already held that ZTE breached a non-disclosure agreement signed between the parties in December 2013. ZTE may request that these communications remain confidential by July 6.
09:18 EDTWYYOn The Fly: Pre-market Movers
Subscribe for More Information
07:45 EDTWYYWidePoint enters into strategic alliance with Samsung SDS America
Subscribe for More Information
June 26, 2015
17:20 EDTVRNGVringo files $50M mixed securities shelf
Subscribe for More Information
June 25, 2015
08:56 EDTEGHT8x8, Inc. management to meet with Deutsche Bank
Subscribe for More Information
June 24, 2015
08:40 EDTVRNGVringo announces creation of JV
Subscribe for More Information
June 23, 2015
08:02 EDTACLSAxcelis receives follow on order for Purion XE high energy implanter
Subscribe for More Information
June 22, 2015
07:06 EDTTBIOTransgenomic plans to launch six new genetic cancer tests this year
Transgenomic announced that it is planning to launch up to six new genetic cancer tests this year based on its Multiplexed ICE COLD-PCR, or MX-ICP, technology. The new tests will focus on actionable genetic mutations and alterations in patients with melanoma, non-small cell lung cancer, or NSCLC, and colorectal cancer, and will include both single tests and multi-gene panels. Transgenomic’s MX-ICP technology has demonstrated exceptional sensitivity and accuracy using either standard tissue or liquid biopsy samples such as blood and plasma. The tests are expected to be available for diagnostic use through Transgenomic’s CLIA-certified laboratory. “We are ahead of schedule in commercializing our pipeline of laboratory-based cancer tests to meet the growing demand for targeted and personalized cancer treatments,” said Paul Kinnon, president and CEO of Transgenomic. “The unsurpassed accuracy of our Multiplexed ICE COLD-PCR technology and its ability to produce highly sensitive and accurate results from small amounts of virtually any type of patient sample enable its broad use for tumor detection and monitoring. The fact that MX-ICP is a platform technology is also facilitating the rapid development of our pipeline. We intend to release two or three new single and panel tests per quarter for the remainder of this year, focusing on the two most prevalent cancers--colorectal and lung, as well as melanoma, which is especially amenable to targeted therapies.”
June 18, 2015
09:32 EDTVRNGVringo granted six-month extension to regain minimum bid price compliance
Subscribe for More Information
08:35 EDTVRNGVringo granted six-month extension by NASDAQ to regain compliance
Subscribe for More Information
08:27 EDTEGHT8x8, Inc. completes acquisition of Quality Software Corporation for $3M in cash
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use